About
Dr Barry Davies is a cancer researcher at Newcastle University with a 16-year publication record (1999-2015) focused on molecular mechanisms in urological and gynecological cancers. His collaborative work spans prostate, bladder, ovarian, and thyroid cancers alongside neuroblastoma studies, primarily within preclinical and translational oncology frameworks.
His research centers on:
- Molecular drivers of metastasis (S100A4, HMGB1)
- Therapeutic targeting of androgen receptors in prostate/ovarian cancers
- COX-2 inhibition for bladder cancer immunotherapy
- Diagnostic biomarkers for thyroid malignancy
- Mechanisms of tumor necrosis in neuroblastoma
- Cell death/proliferation pathways in ovarian epithelium
Analysis of his publications reveals a consistent focus on bridging molecular discoveries with clinical applications. Key trends include investigating S100A4's role in bladder cancer metastasis, developing mutant androgen receptor models for prostate cancer therapy, and evaluating COX-2 inhibitors to enhance BCG immunotherapy. His work emphasizes translational relevance through preclinical models while highlighting limitations of existing diagnostic markers like Mcm-2/Ki-67 in thyroid cancer.
